Additional Information

Description

Ruxience (Rituximab-pvvr) 500 mg/50 mL vial is a biosimilar monoclonal antibody indicated for the treatment of various B-cell malignancies and autoimmune disorders. It is used in patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.

The active ingredient, rituximab-pvvr, binds to CD20, initiating immune-mediated cytotoxicity, complement-dependent cytotoxicity, and direct apoptosis of malignant and overactive B cells. This mechanism is effective in reducing tumor burden in hematologic malignancies and controlling autoimmune inflammation in diseases such as rheumatoid arthritis.

Ruxience is administered as an intravenous infusion, with dosing regimens tailored to the specific condition being treated. Premedication with corticosteroids, antihistamines, and antipyretics is recommended to reduce the risk of infusion-related reactions. Patients should be monitored for infections, hematologic toxicities, and infusion-related adverse events.